EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. Decision date: 11/12…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Onbevzi (bevacizumab)

Snippet

Status: Withdrawn. Therapeutic area: Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms. MAH: Samsung Bioepis NL B.V.. Decision date: 11/12/2023